World Health Organization: Initial review of CBD doesn’t warrant scheduling
WHO Expert Committee on Drug Dependence announced plans to undertake a fuller review of cannabis in 2018
The Cannabist (US)
Wednesday, December 13, 2017
Wednesday, December 13, 2017
CBD, for now, should not be subject to international drug scheduling, a World Health Organization committee determined in an initial review of the cannabis compound. WHO’s Expert Committee on Drug Dependence (ECDD) released findings and scheduling recommendations for more than a dozen substances reviewed at its annual meeting on November 6-10 in Geneva. As part of those findings, the ECDD announced plans to undertake a fuller review of cannabids in May 2018. The initial official guidance on CBD falls in line with expert recommendations. Plans for a deeper review of CBD in May by ECDD will coincide with a "Special Session on Cannabis" evaluating of the cannabis plant and its components, scheduled for May 2018.
tags:
